For managed care organizations and health systems, the recommendations strongly advocated highly selective use of NGS. Routine, nonselective NGS for all sarcoma patients is not justified. Instead, ...
New methods of testing tissue and plasma beyond next-generation sequencing (NGS) could be used to deliver the best ...
Value-based oncology care requires balancing rapid innovation with operational sustainability, equitable access, and ...
Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment ...
The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...
The FDA has granted breakthrough therapy designation to zenocutuzumab (Bizengri) for the treatment of patients with advanced ...
Zook outlined NeoGenomics’ broad menu of over 500 oncology-focused tests and identified therapy selection and MRD markets as representing “more than $40 billion of addressable market opportunity.” He ...
Nutritional Growth Solutions Ltd. ( ($AU:NGS) ) has issued an update. Nutritional Growth Solutions Ltd announced a proposed issue of securities, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback